making the leap from bionano research

to commercialisation

www.quintainconsulting.com.au

Quintain Consulting - Overview

Quintain Consulting Pty Ltd is a private firm, which offers services in the

area of bionanotechnology commercialisation

• Founded in July 2009 by Dr Bob Irving and

Dr Jeanette Pritchard

• Building on knowledge developed during time

at NVA and NanoVic, to offer expert guidance to

government and academic groups, companies

and investors who are involved in

bionanotechnology developments

• Over 40 years combined experience in

biotechnology and bionanotechnology

industries in Australia, UK & Canada

Key Services

• Strategic Advice- For research, development, industrial

and government bodies who are involved or looking to

become involved in bionanotechnology product

development and want to increase their understanding of

local and worldwide markets and opportunities.

• Asset Management- For parties with large and small IP

portfolios.

• Technology Assessment- For funding and investment

groups / individuals who would like an expert opinion on

bionanotechnology opportunities being presented.

• Project and Process Management- Assembly and

management of multisector / multidisciplinary teams.

Management of product development and

commercialisation processes, including input into

Australian and US regulatory issues.

Expertise

Bob has more than 25 years experience in diagnostic and

therapeutic technology development in Australia,

Canada and the UK. He has led programs within CSIRO,

Diagnostics CRCs and biotech companies worldwide and

has been instrumental in the establishment and launch

of start-up companies such as Evogenix.

Bob advises industry bodies and government on

nanotechnology strategy, development and

commercialization, and participated in the Australian

Academy of Technological Sciences and Engineering

mission to France, organised in association with the

National Academy of Technologies of France.

Bob has a PhD through the Imperial Cancer Research

Fund (London, UK) with a research topic on prostate

cancer.

Jeanette has 15 years experience working in device

development, over 8 of which have been within the

biotechnology industry in the UK and Australia. Jeanette

has extensive experience in project management, business

development and commercialisation of devices for rapid,

point-of-care disease detection and on-site water

monitoring.

Jeanette participates in the Victorian Government Skills and

Public Support Working Group, as part of a broad initiative

to develop actions for implementation of the five year

Biotechnology Strategic Plan.

Jeanette completed her PhD at the University of Newcastle

upon Tyne (UK), with a research topic on development of a

detection system for cardiac marker proteins.

Dr Bob Irving

Founder & Director

Dr Jeanette Pritchard

Founder & Director

Current Projects

InCellution

Commercialisation and management of InCellution IP, assigned from AdAlta Pty Ltd. The

InCellution process uses natural somatic hypermutation processes that occur in human B-cells

to produce improved diagnostic and therapeutic reagents. Currently in discussions with

overseas group and investors.

BioDetectors

Engagement by NSW-based start-up diagnostics company BioDetectors Pty Ltd, to manage

its business development and commercialisation activities.

Trinity Bioactives / NanoVentures Australia

Management of the completion of the current phase of the meningococcal diagnostic test

development work.

NanoVentures Australia

Feasibility study of sensing and delivery devices currently being assessed by a medical

devices company.

Identification of Technologies and IP for Sensing and Delivery; Negotiation and Coordination of Licenses and Assignments

Convenient systems (for both patient and healthcare providers) for monitoring health/drug status and delivery of medications require continuous monitoring, signaling and delivery devices with minimal disruption to the patient.

Approach

Evaluated sensing systems in development and available commercially and gained access to sensor IP developed within local university (RMIT). Proposed a sensing and delivery solution to fulfill the needs of the client company. Negotiated License and Assignment Agreements.

Result:Licensing and Assignment Agreements for required technologies completed and

product development plan prepared.

Case Study 1

Case Study 2

Licensing out Transdermal Delivery Technologies for large molecule immunotherapies

Each year in the US alone, 29,000 anaphylactic reactions to foods are treated in emergency departments and nearly 200 deaths occur due to food allergies. Seafood allergies are the most common cause, with life-threatening reactions. Traditionally, anti-allergy or “tolerising” reagents are injected into patients, but more direct access to the immune system is preferred.

Approach (through NVA):

Negotiated Co-Development and Licensing Agreement with the company, for the evaluation and in vivo testing of the Formulation and Transdermal Patch delivery of its anti-allergy therapeutic(s).

Result:

Successful license agreement negotiation and execution.

Managed development plan; coordinated the materials, formulation and testing of the reagents.

The pharmaceutical industry has a need for improved therapeutic and diagnostic antibody-based reagents to provide better health outcomes for patients

As monoclonal and recombinant antibodies become increasingly accessible to the clinic for treating a range of disease states including cancer, it is becoming necessary for these reagents to be optimised for use in humans and in their effectiveness.

Approach (through Diagnostics CRC):

Technologies and expertise in the UK, Germany and Australia were identified and harnessed, and funding to support the team secured. IP was protected. Investment funding was secured to develop the technology into a commercially relevant process. The investment was used to establish a start-up company for this purpose.

Result:The start-up company- EvoGenix- which successfully developed the commercial process went to IPO and then merged with Peptech to form Arana. Arana has now has been acquired by Cephalon (US).

Case Study 3

Develop an understanding and raise awareness of future diagnostics appropriate to the Indonesian region

Improved next generation diagnostic technologies and tests developed in Australia were of interest to researchers, clinicians and diagnostics companies in Indonesia. They needed to have the opportunity to understand and evaluate their applications and to make links with developers of the technologies and tests. State of the Art equipment was readily available but not strategies or expertise for its use.

Approach (through CSIRO):

Coordinated researchers from Institutions and Universities in Queensland and Victoria, along with WHO and Australian Biotechnology Diagnostics Companies, with leaders in the Inter-University Biotechnology Centres in Bandung and Yogyakarta, for a series of Indonesian workshops.

Result:Two 2-day workshops with academic, applied scientists and clinicians from the Centres, Universities and diagnostics companies from across Indonesia. Institutions in Australia supported or provided access to Indonesian researchers for follow-up after the workshops.

Case Study 4

Contact

Suite 213

1 Queens Road

Melbourne VIC 3004

Australia

bob@quintainconsulting.com.au

jeanette@quintainconsulting.com.au

www.quintainconsulting.com.au